BioSpace News Archive

STRATA Skin Sciences, Inc. announced the company will participate in the Inaugural EF Hutton Global Conference at The Plaza Hotel in New York City from May 10-11, 2023.

Benitec Biopharma Inc. today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present at the JMP Securities Life Sciences Conference on Tuesday, May 16th, 2023 at 2:00 pm.

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence.

Olema Pharmaceuticals, Inc. today announced a poster presentation on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in development for the treatment of metastatic breast cancer, at the upcoming ESMO Breast Cancer Annual Congress 2023 taking place May 11-13, 2023, in Berlin, Germany.

Marker Therapeutics, Inc. today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer.

Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in Greater China (Mainland China , Taiwan , Hong Kong , and Macao ). INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.

ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced the opening of the Company’s 21,500 square foot Good Manufacturing Practices (GMP) facility in Los Angeles, California.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”) today announced an upcoming presentation at the International Society of Investigative Dermatology (ISID) International Epidermolysis Bullosa Symposium, which is being held in Osaka, Japan through May 9, 2023.

Predictive Oncology Inc. (NASDAQ: POAI) today announced that it will report its financial results for the first quarter ended March 31, 2023 after the market close on Monday, May 15, 2023.

Eyenovia, Inc. (NASDAQ: EYEN) today announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired.